As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness and proper prevention crucial. Recognising this urgent public health concern ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

It is a mistake to claim that there is not widespread research into the effectiveness of vaccines, especially those given to ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

RSV is very common—most kids get it by age 2, according to the CDC. For older children and adults, it often feels like a cold. But for infants, RSV can be much more serious.

Key takeaways: The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike nirsevimab, which has weight-based dosing, clesrovimab has a fixed dose.